

Phone: 1-800-809-1265 Fax: 1-866-872-8920

					í.
Referral	Status:		MRN:		
	New referral	Order ch	ange	Order Renewal	
atient	preferred clinic:				

Fabrazyme® (agalsidase beta) Standard Plan of Treatment

PATIENT DEMOGRAPHICS:										
Date of Referral:		Patient's Phone:								
Patient Name:				Address:						
Date of Birth:				City, State, Zip:						
Height in inches:	Weight:	LB or	KG	Gender:	Allergies:		See list	NKDA		

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

E75.21 - Fabry Disease

	Other:							
REQ	UESTED DOCUMENTATION:	PREVIOUS ADMINIS	TRATIC	DN: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?				
1	Insurance information	IF NO:	IF YES	:				
2	Most recent History & Physical	PLEASE STATE	LAST I	ST INFUSION DATE:				
3	Full medication list		FROM PREVIOUS	REQUIRED WASHOUT	EQUIRED WASHOUT NEXT INFUSION DATE:			
4	Tried and failed therapies		RAPY: IF ORDER CHANGE:					
5	Serum IgG and GL-3 level			Continue ourrent order until incurence enpressed				
6				Continue current order until insurance approved				

MEDICATION ORDERS:

NOTE: We may require a detailed Letter of Medical Necessity or clinical supporting documentation (depending on diagnosis), to be able to verify eligibility and payment for this treatment through Medicare and/or other insurance plans.

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

*FDA labeling suggests pre-medication with an antihistamine and antipyretic in patients who experience infusion reactions

IV Methylprednisolone 40mg 125mg Other:	
Famotidine 20mg 40 mg	
Other:	

n patients who experience initiation reactions.									
PO	Acetaminophen		325mg		500mg		650mg		1000mg
	Famotidine		20mg		40mg				
	Diphenhydramine		25mg		50mg				
	Fexofenadine		60mg		180mg		_		
	Cetirizine		10mg						
	Loratadine		10mg				_		
	Other:								

Refills x 12 months unless noted otherwise here:

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

MEDICATION:

Fabrazyme[®] (agalsidase beta) IV in 50 -- 500mL of NS

<u>Patients \geq 30kg</u>: Initial infusion should be administered at 15mg/hr. Increase in increments of 3-5mg/hr with subsequent infusions as tolerated, with a minimum infusion time of 1.5hr.

Patients weighing < 30kg: Infuse at a maximum rate of 15mg/hr.

DOSE:

1mg/kg Other:

FREQUENCY:

Every 2 weeks Other:

LINE USE/CARE ORDERS:

SPECIAL/LAB ORDERS:

Flush device per facility standard	flushing procedure	adverse reaction orders, which can be found at our website or scan here.	
PRESCRIBER INFORMATION:			
PROVIDER NAME:		PHONE:	
ADDRESS:		FAX:	
CITY, STATE, ZIP:		NPI:	
PRESCRIBER SIGNATURE: (No stam	np signatures)		DATE:
Dispense as written/Brand m	nedically necessary	Substitution Permitted	